1. Introduction
===============

Recently, endoscopic submucosal dissection (ESD) has become the standard procedure for treating gastric neoplasms, such as gastric adenoma and early gastric cancer (EGC). ESD can achieve a higher *en bloc* resection rate than endoscopic mucosal resection, regardless of the lesion size.^\[[@R1]\]^ However, the size of the artificial ulcers induced by ESD is large. It is well known that the large resected specimen size is an independent risk factor for delayed bleeding.^\[[@R2]\]^ To decrease the risk of delayed bleeding, both prophylactic coagulation of visible vessels on the ulcer base and administration of proton pump inhibitors (PPIs) are performed after ESD.

Inhibitors of gastric acid secretion, such as PPIs, have been administered after ESD to induce rapid ulcer healing. Recently, the effects of vonoprazan, a novel potassium-competitive acid blocker, have been evaluated with respect to ESD scars. Several studies have reported that vonoprazan is superior to PPIs for healing artificial ulcers, suggesting that the results may be due to its higher acid-inhibitory effects.^\[[@R3]--[@R6]\]^ However, other studies have shown that there is no significant difference between vonoprazan and PPIs.^\[[@R7],[@R8]\]^ With respect to PPIs, several studies have reported that a higher dose of PPIs results in higher gastric pH.^\[[@R9],[@R10]\]^ Previous studies have compared the effectiveness of standard-dose vs half-dose rabeprazole and lansoprazole.^\[[@R11],[@R12]\]^ Half-dose PPIs showed a comparable effect on artificial ulcer healing to that of standard-dose PPIs.^\[[@R10],[@R11]\]^ Thus, it remains unknown whether higher acid suppression using vonoprazan is necessarily associated with a higher ulcer healing rate. Given that vonoprazan is currently not available in all countries, double-dose PPIs can be considered as a replacement for vonoprazan, because the double dose of PPIs showed stronger acid suppression than the standard dose, although its potential is not the same as that of vonoprazan. Thus, the aim of this study was to compare the standard dose of PPIs with the doubled dose of PPIs to extrapolate the effect of vonoprazan on ESD ulcers through stronger acid suppression by doubling the dose of PPIs administered to patients after ESD. Moreover, this prospective randomized controlled study was conducted to evaluate whether artificial ulcer healing after ESD is faster when increasing the dose of the PPI esomeprazole from 20 mg (standard dose) to 40 mg (double dose).

2. Methods
==========

2.1. Patients, randomization, and masking
-----------------------------------------

Patients who underwent ESD for gastric mucosal neoplasms from July 2017 to December 2017 at Pusan National University Yangsan Hospital were eligible for enrollment in this study. During the study period, 200 patients who required gastric ESD for gastric neoplasms were considered for inclusion. Three patients refused to participate. Finally, 197 patients were randomly assigned to the standard-dose (20-mg/day esomeprazole) and double-dose (40-mg/day esomeprazole) groups. Randomization was performed using computer-generated randomization lists. The endoscopists who performed the ESD and follow-up endoscopy were unaware of the patients' treatment group.

Five patients were excluded from the analysis during the study period. Two patients in the standard group did not visit our hospital after ESD. Therefore, those patients could not be followed up to evaluate ulcer healing after 4 weeks of PPI treatment. One patient in the standard group underwent an additional gastrectomy due to noncurative resection of ESD. In each group, 1 patient developed hematemesis requiring readmission and treatment (endoscopic coagulation and high-dose PPI infusion) and was dropped out of the study. The remaining 192 patients completed the study protocol (Fig. [1](#F1){ref-type="fig"}).

![Flow chart of the participants. ESD = endoscopic submucosal dissection.](medi-98-e15701-g001){#F1}

Patient and lesion characteristics, such as sex, age, initial diagnosis, location of the lesion, endoscopic findings, and body weight, were recorded. Abdominal computed tomography was performed to confirm the absence of perigastric or distant lymph node metastasis in patients with pre-ESD biopsy results indicating adenocarcinoma. This study was approved by the ethics committee of the Institutional Review Board of Pusan National University Yangsan Hospital (RCT no.: KCT0002885), and written informed consent was obtained from all patients before ESD.

2.2. ESD procedure
------------------

ESD was performed by 2 skilled endoscopists (CCW and KSJ). Marking dots around the lesion were made using argon plasma coagulation. A fluid mixture (consisting of 10% glycerol and 5% fructose in a normal saline solution) with a small amount of indigo carmine and epinephrine was injected into the submucosa. A round hole was made after grasping the mucosa using a pair of coagulation forceps (Endo Cut Q mode). A circumferential incision into the mucosa was made using an insulation-tipped (IT) diathermic knife (KD-610L; Olympus Optical Co, Ltd, Tokyo, Japan) after inserting the insulated tip into the round hole. Direct dissection of the submucosal layer was carried out with an IT knife. A high-frequency generator (VIO 300D, ERBE Elektromedizin Ltd., Tübingen, Germany) was used for marking, gastric mucosa incision, and gastric submucosa dissection.

2.3. Evaluations after 4 weeks
------------------------------

All patients were administered either 20 or 40 mg of esomeprazole daily starting on the morning when ESD was performed. Patients were allowed oral intake after second-look endoscopy the next day, unless serious complications occurred. Follow-up endoscopy was performed at 4 weeks after ESD. Artificial ulcers were evaluated using photographs taken from the same view as those taken immediately after ESD. The dimensions of the initial ulcer were measured from the pathologic specimen, and the dimensions of the ulcer after 4 weeks were measured using biopsy forceps. The ulcer contraction rate was assessed by calculating the percent reduction in size from the initial ulcer size after ESD \[(initial ulcer size -- ulcer size after 4 weeks/initial ulcer size) × 100\]. The size of the ulcer was calculated using the following formula: initial ulcer size = π(R/2)^2^ (measured using the pathology specimen), and ulcer after 4 weeks = π(r/2)^2^ (measured using forceps) (Fig. [2](#F2){ref-type="fig"}).

![Measurement of the ulcer size and calculation of the ulcer contraction rate.](medi-98-e15701-g002){#F2}

2.4. Statistical analysis
-------------------------

Statistical comparisons between the 2 groups were performed using the Student *t*-test, and the correlations between the ulcer contraction rate and drug dose per body weight were determined using a linear regression analysis. Factors associated with scar change were analyzed using a logistic regression analysis. The correlations between drug dose (20 and 40 mg) and the scar change rate were analyzed using Fisher\'s exact test. *P* \< .05 was considered statistically significant. Statistical analyses were performed using SPSS (version 21, IBM Corp., Armonk, NY).

3. Results
==========

3.1. Baseline characteristics
-----------------------------

A total of 192 patients were randomly assigned to the standard-and double-dose groups and completed the study protocol. There were 115 low-grade dysplasia cases, 5 high-grade dysplasia cases, 64 EGC cases, 1 lipoma case, and 2 gastritis cases treated by ESD. Baseline characteristics were not significantly different between the treatment groups (Table [1](#T1){ref-type="table"}). One patient in each group underwent ESD without discontinuing the dual antiplatelet therapy (aspirin and clopidogrel) because of a high cardiovascular risk. In most situations when the patient required antiplatelet therapy, such as if they had previously underwent cardiovascular stent insertion, the patients were only administered aspirin without clopidogrel.

###### 

Baseline data of the treatment groups.
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3.2. Comparison of the PPI dose effect between the groups
---------------------------------------------------------

The ulcer contraction rate (86.5% in the 20-mg group vs 86.3% in the 40-mg group, *P* = .91) or scar-change rate (30.9% vs 30.6%, *P* \> .99) were not significantly different between the groups (Table [2](#T2){ref-type="table"}). In a univariate analysis, initial ulcer size, antiplatelet drug use, and EGC were associated with delayed ulcer healing. A multivariate analysis showed that the initial ulcer size \[odds ratio (OR) 0.24; 95% confidence interval (CI) 0.11--0.50\] and EGC as the final pathologic result (OR 0.22; 95% CI 0.08--0.58) were independent risk factors associated with delayed scar changes in artificial ulcers (Table [3](#T3){ref-type="table"}).

###### 

Comparison of ulcer contraction and scar change rates.
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###### 

Results of the univariate and multivariate analyses of factors associated with delayed scar change.
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4. Discussion
=============

Pepsin activity, an important attacking factor for the gastric mucosa, is pH dependent. Therefore, a reduction in gastric acidity could accelerate the healing of gastric ulcers. Several studies have reported that PPIs were more effective than histamine-2 receptor agonist in healing ulcers and preventing delayed bleeding due to the higher acid suppression efficacy of PPI than histamine-2 receptor agonist.^\[[@R13],[@R14]\]^ Therefore, PPIs are commonly used to prevent bleeding and promote ulcer healing after ESD.^\[[@R15],[@R16]\]^

In this study, the scar change and ulcer contraction rates of ESD ulcers on day 28 were not statistically different between patients administered 20 mg and those administered 40 mg of esomeprazole. In a previous study evaluating acid inhibition according to esomeprazole dose, 40-mg esomeprazole showed stronger acid inhibition compared to 20-mg esomeprazole.^\[[@R9]\]^ Therefore, our results suggest that stronger acid suppression does not guarantee faster artificial ulcer healing. Several other studies have reported that the rate of artificial ulcer healing was not significantly different between treatment with half doses of PPIs (lansoprazole and rabeprazole) and that with usual doses of PPIs.^\[[@R11],[@R12]\]^ A study showed that vonoprazan, a novel oral strong acid blocker approved in Japan, was not significantly different than 30-mg lansoprazole for artificial ulcer healing after ESD.^\[[@R6]\]^ On the other hand, recent studies on vonoprazan have shown that it was superior to the usual dose of 20-mg rabeprazole or 20-mg esomeprazole for ESD-induced ulcer healing.^\[[@R4],[@R5]\]^ Several studies report faster artificial ulcer healing with vonoprazan, suggesting that strong acid suppression may result in this difference.^\[[@R3]--[@R6]\]^

A possible reason for the inconsistent results is as follows. The factors influencing the artificial ulcer healing process are different from those influencing the healing of peptic ulcers. Fibrosis from peptic ulcers caused by chronic inflammation inhibits blood flow and mucosal regeneration. In contrast, the increased blood flow at the margin of the artificial ulcer may promote ulcer healing. A well-conditioned environment to promote faster ulcer healing may decrease the differences in the effects of various acid suppressors.

In this study, specimen size was an independent risk factor for delayed scar changes in artificial ulcers. Several studies have reported that a large resected specimen was a risk factor for delayed bleeding.^\[[@R2],[@R17]\]^ Moreover, another recent study showed that initial ulcer size and ulcer location are independent risk factors for delayed ulcer healing.^\[[@R18]\]^ Our results also support those results, because an unhealed artificial ulcer was the main cause of delayed bleeding. Another risk factor for delayed scar change in an artificial ulcer was adenocarcinoma as the underlying pathology. The specimen size required to resect EGC lesions tended to be larger than that required for other pathologic results. A minimum of 2-mm distance from the lesion to the margin of the specimen is needed to achieve curative resection for EGC, because ESD specimens are examined by serial sections at 2-mm intervals. Leaving enough margin to achieve a curative resection for EGC can result in a large ulcer size, and might be the reason for the delayed scar changes in artificial ulcers in patients with EGC.

Delayed ulcer healing can increase the risk of post-ESD bleeding. The bleeding can result in hypovolemic shock and severe anemia. Therefore, an effort to promote artificial ulcer healing is important to reduce the risk of delayed bleeding. If the size of the ulcer after ESD is larger than expected, the combination of an acid-suppression agent and a cytoprotective agent could provide a beneficial effect greater than that of strong acid suppression in the healing process of artificial ulcers.^\[[@R19]\]^

This study has some limitations. First, the study was conducted at a single center. Second, the number of patients with large ulcers was too small to confirm that there was no difference in the efficacy for ulcer healing between the 2 groups. In the future, a head-to-head, multicenter, randomized controlled study comparing half, standard, and double-dose PPIs and vonoprazan needs to be conducted, which might help in determining the most cost-effective drug and dose.

A 40-mg dose of esomeprazole has an effect on ESD-induced ulcer area reduction similar to that of a 20-mg dose. This result suggests that strong acid suppression does not necessarily result in rapid artificial ulcer healing.
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